Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Fair point Neil
Probably more via Twitter than RNS, can't imagine that potential customers are monitoring the RNS news feed.
How many major contracts are we seriously going to be get over Twitter?
https://twitter.com/NovacytGroup/status/1382409859187019779?s=19
SP Was well north of £8 months ago,we have New Products now and were is the SP today,so what that does that say for the future,till then we live in hope,in days gone by we were kept up with operations etc,sadly not now.
Van.....I kinda agree with what you said, that's why earlier I said to someone who was thinking of selling...we have to give the new products time....I personally will reassess the situation in 3 months time....by then I hope we are north of £8
Still chewing a real long shot. Trials using plasma with antibodies , Its old school if it was any good it would have been done at the start I am sure. But we have never has such volume of testing before, that could potentially be matched to a specific variant? Ticks the LFT test in a medical setting, and the need for high accuracy.
Probably nothing to do with us, but interesting.
https://www.bidstats.uk/tenders/2021/W14/748290147
Glad to hear that most people today appear to think the dispute with the Govt will be resolved.
Personally, I'm not so sure as this Govt can act totally irrationally, unreasonably and without integrity no matter what the situation. Regards our CEO being awarded a knighthood or being guilty of deception, the two are not necessarily polar opposites with the latter being a pre-requisite for an honour in some circles.
@Bluelight - Thanks for the SXX summary. I'd forgotten the issues there and was just about to have a gander
Big difference there being sxx had huge debt and needed money to move forward. We have the opposite problem, no debt and looking for good investments with our cash pile. Situations not close to comparable in my view.
I'm sorry guys, but a dispute like this you DO NOT resolve through legal people. The commercial people will have to make a call on that. For sure.
Done it many times. Yes, in the UK and yes for very large amounts.
That is also why I said it's crazy that NCYT put out that RNS.
MS
Saintsmith I'm also confused however I still think it's the original antibody test fluffed out in all its glory and we still await the more informative test, happy to be told I'm wrong in which case I would expect an Rns for official launch tomorrow, all these technical terms lol,
This is what I fear most about any company going silent like this - AircraftMechanic - happened before bad news for investors with SXX
**************************************************************************
Oh please don't remind me about SXX, at least I didn't have much in those.
Hamsters - there's PLENTY of room on Dylan's naughty step and we can always make more room if necessary! Lol
ak_gabba; Reverse order for me, We all need to be together at this time!
They could cool off on the naughty step with our Dylianaire?
I would add a 4th RNS announcing a kick asp rapid LFT test, better still a PCR test in 5 mins, and cheaper than other LFTs.
that would be lovely hamsters18
RNS 1. Dispute over DHSC contract has been resolved amicable with no impact on Q4 revenue (DHSC are terribly sorry)
RNS 2. VariPlex is a rip roaring success and we are struggling to keep up with demand both domestically and internationally (but we will)
RNS 3. GM respectfully and politely asks VanV and porky to call a truce :)
As a previous poster mentioned the other day, maybe tomorrow at 16.15 to coincide with a year ago and catch the shorters out before the close?
I would probably normally agree, but after last week we could really do with a 7am RNS or 3 (good ones) to cheer us up.
Nice chunky buys showing up:
17:23:37
437.008
5,806
£25.37k
17:05:42
424.90
13,000
£55.24k
16:54:57
433.37316
50,664 l
£219.56k
Im going for 3 RNS,s from GM before 6.30pm Friday,keep them pants handy Sharedealer.GLA.
VAnV - the consequences of any 'long term plan' not coming up to expectations of the 'market' is the risk that we are taking here before the end of Q2 - sp will ........ we continue to wait and see - not always a good investment strategy - having a belief in a company and being tested like this. Better comms from NCYT req'd.
The problem with Randox is the government influence but also the lack of accuracy .
Randox are also wrapped up in a few backhand scandals with government!!
https://mobile.twitter.com/jolyonmaugham/status/1323921852931149824?lang=en
https://bylinetimes.com/2020/11/02/minister-meetings-fuel-conservative-procurement-scandal/
https://amp.theguardian.com/world/2020/nov/04/tory-linked-firm-involved-in-testing-failure-awarded-new-347m-covid-contract
Disgraceful but typical I suppose!!
SteveV - then it will the next quarter if nothing forthcoming this quarter, etc. Hope you're right though.
Van....as per the rns : The company continues to have limited visibility over future sales!
How can you say that in the middle of a worldwide pandemic
Kaeren, You've hit the nail on the head with that post
I agree with Soder and had I not bought several times would stll be in profit. I swim against the tide here but this contract dispute may be resolved amicably. I think they are an outstanding diagnostoc company , first to market with a covid test , first to market with their Snpsig offering and no doubt their R and D will be fast to bring to market more products. GM must be under extreme pressure too, there must be a reason for his radio silence . Im sure he didnt wake up and think lets make the sp tank unless I am delusional. Im as frustrated as everyone and my paper profit has totally evaporated but GM has gone from some calling for him to be knighted to a CEO who many now see as deceptive. I too await news and will base my decisions on that. Re predictions for next few years, I dont think until we are informed more about the contract dispute or see what is in GM's roadmap that any accurate numbers can be forcast. K
This is from the link Wilson posted from primerdesigns blog today .
14
Apr
COVID-19
Advancing technology and a unique wealth of knowledge are the driving forces behind innovative development in our PathFlow® portfolio of diagnostic tests for infectious diseases.
Our latest addition to the range – the PathFlow® SARS-Cov-2 IgG – is an easy-to-use, rapid, lateral flow test for the detection of COVID-19 antibodies.
It’s a natural evolution in the Novacyt Group’s range of COVID-19 diagnostic solutions, building on our growing expertise in this field, plus our ability to maximise the potential of our technologies and science.
The PathFlow® SARS-Cov-2 IgG rapid test cassette offers a fast turnaround time, with results in as little as 10 minutes – which in some cases is half the time of other products on the marketplace.
The design of PathFlow® assays capitalises on the utilisation of colloidal gold particles as detector reagents. This delivers a high performing and reliable method for detecting antibodies to the ‘S’ protein receptor binding domain (RBD) and in the ‘N’ proteins of SARS-CoV-2 in human whole blood, plasma or serum.
The new test not only identifies people who have built up antibodies in response to being infected with SARS-CoV-2, but can also be used to assess an individual’s response to immunisation. Understanding if someone has developed an immune response to SARS-CoV-2 as a result of either infection or vaccination is a pivotal step forward, not only in our understanding of the virus but also in our ability to combat it.
We’ve developed the PathFlow® SARS-CoV-2 rapid test to be used for sero-surveillance and assessing vaccine efficacy. Potential applications include academia and research, immunity passports and for corporate use in assessing employee immunity.
Track record
The new test builds on the past 18 months of our Novacyt product development and innovation in developing assays to help assess and manage the COVID-19 pandemic.
This includes innovative product development in our PathFlow® portfolio – part of our Microgen Bioproducts division – where the new SARS-CoV-2 IgG rapid test is a natural addition to a fast-growing range of assays for the rapid diagnosis of infectious diseases.
With more than 20 years’ experience in the food industry, helping food manufacturers ensure consumer safety, our PathFlow® research and development team has an established track record. We have since utilised our growing expertise and knowledge base to create a broad range of high-quality diagnostic products for clinical use. Offering accurate, rapid & cost-effective detection methods for many common bacterial & viral infections – alongside key toxins and biomarkers.
As part of the Novacyt Group, Microgen Bioproducts and the PathFlow® portfolio benefit from synergies with other group divisions, sharing knowledge, expertise and experience across a rapidly growing, international diagnostics organisation, which special